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Abstract
Introduction: Hypoxia is a feature of the inflamed synovium in rheumatoid arthritis (RA). Intra-articular injection of
hyaluronan (HA) may be considered a potential way to treat RA. However, the exact molecular mechanism of HA
on decreased cellular responses to hypoxic environment is unclear. The present study has been designed to use
the adjuvant-induced arthritis model to examine the effects of HA on the changes of immunohistochemical
expressions of hypoxia-inducible factor-1alpha (HIF-1alpha), inducible nitric oxide synthase (iNOS), and matrix
metalloproteinase-3 (MMP3) in the synovial tissues at the early phase of arthritic inflammation.
Methods: Monoarthritis was induced in adult male Sprague-Dawley (250-300 g) via intraarticular injection of
complete Freund’s adjuvant (CFA) into the tibiotarsal joint. The CFA-induction arthritis animals were divided into
three groups: treatment (intraarticular injection of HA), placebo (intraarticular injection of saline) and controls (no
treatments). Functional evaluations of edema and pain behavior, histology, and HIF-1alpha, iNOS, and MMP3
immunohistochemistry were performed before, after the first injection, three injections, and on the follow-up
injection of the treatments.
Results: Intra-articular injection of HA also significantly suppressed the mechanical allodynia (p < 0.001) and
overexpressions of HIF-1alpha (p < 0.001), iNOS (p = 0.004) and MMP3 (p < 0.001) immunoreactivity in synovium.
Conclusions: This study demonstrated that early intervention of HA is an effective protection against accumulation
of inflammation-induced HIF-1alpha, iNOS, and MMP3 to limit erosive damage in CFA-induced model of arthritis.
Introduction
A hypoxic microenvironment is a hallmark of the
inflamed synovium and its importance in the pathogen-
esis of rheumatoid arthritis (RA) has been documented
[1-4]. In human and animal arthritis models, the impor-
tance of hypoxia for the development and persistence of
RA has been demonstrated [1,5]. Previous studies have
demonstrated the hypoxic nature of the synovium of
patients with RA and the constitutive expression of
hypoxia-inducible factor-1-alpha (HIF-1a), a key
regulator of hypoxia transcriptional response. In RA
joints hypoxia has been shown to express increased
amounts of HIF-1a and HIF-1 target genes in synovial
lining cells and articular chondrocytes under hypoxic
conditions, which aggravate joint inflammation [6,7].
Previous studies also demonstrated that hypoxia takes
place in the synovium at the pre-arthritic stage or early
stage of the disease and has a close spatial relationship
and positive severity correlation with synovitis [8].
Therefore, HIF-1a is identified as a key player in the
pathogenesis of RA and a potential therapeutic target in
RA development.
Nitric oxide (NO) synthesized from arginine by nitric
oxide synthases (NOS) is an important chemical media-
tor of inflammation. The inducible isoform of NOS
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any medium, provided the original work is properly cited.(iNOS) is primarily responsible for producing large
amounts of NO and its overexpression has been
linked to the progressive inflammation and tissue
destruction observed in hypoxic experimental arthritis
[9,10] and human rheumatoid synovium [11,12].
Matrix metalloproteinases (MMPs), the most impor-
tant matrix-degrading enzymes in RA, act as key
mediators of the resorption of cartilage, bone, syno-
vial fluid, and adjacent soft tissue, and this resorption
occurs as part of the pathological destruction of joint
tissue [13]. Among dozens of MMPs, MMP3 (strome-
lysin 1) has been reported to be the major enzyme
produced by fibroblasts and macrophage-like cells in
the synovium, and the level of MMP3 has been
reported to be significantly higher in synovial fluids
from patients with RA [14-16]. Under the inflamma-
tory conditions of RA, the levels of HIF-1a,i N O S ,
and MMP3 are significantly higher in synovial fluids
in previous studies and thus are implicated in the
pathogenesis of RA. Expressions of iNOS and MMP3
a r ep r o b a b l yr e g u l a t e db yH I F - 1 a in the cellular
response to hypoxic and inflammatory environments
[11,17,18]. Therefore, inhibition or downregulation of
these molecules (or both) may exert anti-hypoxic and
anti-inflammatory effects.
Hyaluronan (HA) is a polymer of disaccharides and
has a high capacity for holding water and possesses high
viscoelasticity [11]. The intra-articular supplementation
of HA can replace synovial fluid, which has lost its vis-
coelastic properties. HA has been widely used for the
treatment of osteoarthritis (OA) [19]. HA not only is a
lubricating agent but its exogenous administration can
suppress the expression of inflammatory cytokines,
MMPs, and free oxygen radicals to reduce inflammation
in a post-laminectomy rat model [20] and patients with
RA [21]. Therefore, it has been expected that the intra-
articular injection of HA is more efficacious in treating
RA, which principally characterizes articular synovitis
[21,22]. However, for RA joint treatment, the clinical
use of HA is still rare because its immunoregulatory
action is still debatable.
Complete Freund’s adjuvant (CFA)-induced arthritis
shares some characteristics of RA. This model mirrors
much of the pathology of RA, including hyperplasia of
the synovial tissues, inflammatory infiltration of the
joints, and destruction of bone and cartilage in the syno-
vial joint [23]. The present study has been designed to
use the adjuvant-induced arthritis model to examine the
effects of HA on the changes of immunohistochemical
expressions of HIF-1a, iNOS, and MMP3 in the synovial
tissues in the early phase of arthritic inflammation. We
hypothesize that the addition of HA will alleviate
inflammatory nociception and impede the accumulation
of arthritis-induced HIF-1a, iNOS, and MMP3 produc-
tion in the early phase of the experimental arthritic
inflammatory joint. This hypothesis, if correct, will offer
at least a partial explanation for the efficacy of topical
HA application in the subsequent inhibition of hypoxic
inflammation in this preclinical model.
Materials and methods
General design
Arthritis was induced in all animals by intra-articular
injection of CFA. After a day of CFA induction, the
arthritic animals were randomly divided into one of three
groups (n = 30 per group) according to the treatment
administered: (a) the ‘no treatment’ (No-tr) group, which
consisted of controls that received a sham injection by
needling (that is, no solution was administered); (b) the
SA, or placebo, group, which received 50 μL of saline;
and (c) the HA group, which received 50 μLo fH A .
Injections for all three groups were intra-articularly
administered. Injections of HA or saline were given every
2 days (days 2, 4, and 6). The evaluation instruments
were edematous swelling of the paw, pain behavioral
assessments, histology, and immunohistochemistry.
Assessments were performed at day 0 (pre-arthritic),
day 1 (post-arthritic), 3 hours after the treatment of
one injection (one dose, 1D) on day 2, after three
injections (three doses, 3D) on day 6, and 6 days after
three doses (3D6d) on day 12. A flow diagram is pre-
sented in Figure 1.
Day 0                1                2               3                4                5               6                         12
Post-treated evaluation
Sacrificed
Pre-arthritic
evaluation
CFA 2nd
HA/SA
3rd
HA/SA
1st
HA/SA
Post-arthritic
evaluation
Post-treated evaluation
Sacrificed
Post-treated evaluation
Sacrificed
1D of HA, SA, and 
No-tr groups
3D6d of HA, SA, and 
No-tr groups
3D of HA, SA, and 
No-tr groups
Figure 1 Experimental design of the sequence of events for the entire course of the experiment. After evaluations that included
measurements of paw edematous swelling and pain threshold, the animals were sacrificed for histology and immunohistochemistry. 1D, one
dose; 3D, three doses; 3D6d, follow-up at the 6th day after three doses; CFA, complete Freund’s adjuvant; HA, hyaluronan; No-tr, no treatment;
SA, saline.
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Ninety adult male Sprague-Dawley (SD; purchased from
BioLASCO Taiwan Co., Ltd., Taiwan, Republic of
China) rats weighing 250 to 300 g were kept in the
Laboratory Animal Center of China Medical University.
An effort was made to minimize discomfort and to
reduce the number of animals used. All animal experi-
ments were conducted with the approval of the Animal
Care and Use Committee of China Medical University
in accordance with the Guidelines for Animal
Experimentation.
Induction of monoarthritis
Monoarthritis was induced by an injection of CFA into
the unilateral ankle articular cavity. The rats were briefly
anesthetized with 4% isoflurane (AERRANE; Baxter
Healthcare Corporation, San Juan, Puerto Rico). A 28-
gauge needle was vertically inserted distally into the
articular cavity from the gap between the tibiofibular
and tarsus bone. CFA with a volume of 50 μL (10 mg of
mycobacterium, F5881; Sigma-Aldrich, St. Louis, MO,
USA) was then injected. The monoarthritic animals
were placed separately in clear acrylic containers (10.5-
inch width × 19-inch diameter × 8-inch height), and
free movement was allowed for at least 24 hours to let
the animals adjust to these conditions before any experi-
mentation was performed.
Ultrasound-guided hyaluronan injection
While the animals were under brief isoflurane anesthe-
sia, ultrasound (Terason t3000™ Ultrasound System;
Terason Division, Teratech Corporation, Burlington,
MA, USA)-guided injection was performed on the lat-
eral side of the tibiotarsal joint, and the transducer in
the sagittal plane showed the distal end of the tibia and
proximal part of the tarsus in the image plane. Needle
insertion was performed perpendicularly to the transdu-
cer. HA injection (molecular weight of 1.2 to 1.4 × 10
6
Da; Ostenil
®, 10 mg/mL sodium hyaluronate; TRB Che-
medica AG, München, Germany) was documented by
recording an image clip during injection with the needle
tip in the image plane.
Pain threshold assessment
The pain thresholds were determined by nociceptive
thresholds to mechanical stimulation. The test consisted
of evoking a hind paw flexion reflex with a handheld
force transducer (electronic von Frey anesthesiometer;
IITC Inc., Woodland Hills, CA, USA) adapted with a 0.5
mm
2 polypropylene tip. In a quiet room, the rats were
placed in acrylic cages (32 × 22 × 27 cm high) with a
wire grid floor for 15 to 30 minutes of habituation prior
to testing. The polypropylene tip was applied perpendi-
cularly to the central area of the hind paw with
sufficient force to bend the filaments into an ‘S’ shape
for 3 to 4 seconds. The test consisted of poking a hind
p a wt op r o v o k eaf l e x i o nr e f l e xf o l l o w e db yac l e a r
flinch response after paw withdrawal. Testing was
initiated with the filament corresponding to 20 log of
f o r c e( g ) .T h ef i l a m e n t sw e r ea p p l i e dw i t hag r a d u a l
increase in pressure until a withdrawal reflex response
was finally detected from the animal. The response to
this filament is defined if a series of weaker or stronger
filaments would be tested. The weakest filament able to
e l i c i tar e s p o n s ew a st a k e nt ob et h ep a ww i t h d r a w a l
threshold (g). The intensity of the pressure was
recorded, and the final value for the response was
obtained by averaging five measurements.
Measurement of edematous swelling of the paw
The extent of peripheral swelling was assessed by mea-
suring the circumference of the paw at intact and CFA-
injected sites with a flexible tape. The paw circumfer-
ence was obtained by averaging three measurements.
The difference in the ankle circumference between the
initial value (pre-arthritic data) and that at each time
point after injection is expressed as change (percentage)
= 100% × [(post-arthritic circumference)-(pre-arthritic
circumference)]/(pre-arthritic circumference). All assess-
ments, including paw withdrawal and swelling measure-
ments, were performed with the assessor blinded with
respect to treatment.
Histology and immunohistochemistry
Animals were killed by anesthetic overdose after treat-
ments of 1D (n = 10 for each group), 3D (n = 10 for
each group), and 3D6d (n = 10 for each group) on days
2, 6, and 12. Hind ankles were collected for histological
and immunohistological analysis. The formalin-fixed,
paraffin-embedded joint tissues (including synovium and
cartilage tissues) were cut at a thickness of 5 μm for his-
tology and immunohistochemistry. Histological confir-
mation of the arthritic pathology was performed with
hematoxylin and eosin-stained sections. Sections were
deparaffinized in 200 mL of Trilogy (Cell Marque Cor-
poration, Rocklin, CA, USA) and incubated with 3%
H2O2 in methanol for 20 minutes at room temperature.
Subsequently, sections were treated with proteinase K
(Sigma-Aldrich) at 0.1 mg/mL for 20 minutes at room
temperature to unmask epitopes and this was followed
by phosphate-buffered saline (PBS) rinse. Sections were
incubated with blocking buffer (Power Block™;B i o -
genex, Fremont, CA, USA) for 2 hours at room tem-
perature followed by incubation overnight at 4°C with
the mouse monoclonal antibody anti-HIF-1a (diluted
1:100; Thermo, Fremont, CA, USA) and with the follow-
ing rabbit polyclonal antibodies: anti-iNOS (diluted
1:200; Thermo) and anti-MMP3 (diluted 1:200;
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PBS containing 0.05% Tween-20 for 10 minutes, sec-
tions were incubated with biotinylated anti-rabbit and
anti-mouse immunoglobulins (Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA, USA) followed by a
30-minute peroxidase-conjugated streptavidin incuba-
tion (Jackson ImmunoResearch Laboratories, Inc.). Sec-
tions were incubated with 3,3’-diaminobenzidine
(Biogenex), dehydrated, and cover-slipped with Per-
mount (Sigma-Aldrich, St. Louis, MO, USA). Negative
controls were performed by substituting the primary
antibody with non-immune serum.
The histopathology of synovium was analyzed by the
non-parametric scoring system described by Smith and
colleagues [24]. The scores ranged from 0 to 3 for each
of the tissue criteria, including intimal hyperplasia, lym-
phocytic infiltration, subintimal fibrosis, and vascularity.
The higher aggregate score was considered to reflect
increased pathological changes. Five randomly selected
sections were scored and repeated two times for statisti-
cal analysis. Quantitative analysis of immunostainings
was carried out by light microscopy in synovial tissue
lining the joint cavity and synovial tissue attached to the
cartilage. The number of HIF-1a,i N O S ,a n dM M P 3
immunoreactive cells was counted among at least five
alternate sections in the more representative fields by
using a microscope. Positive nuclei and cytoplasm stain-
ing cells for HIF-1a, iNOS, and MMP3 were counted in
high-power fields (× 200 magnification) that contained
synovial lining cells. The area sizes of high-power fields
were calculated by using a stage micrometer (with 100
gradations of 0.01 mm each) when viewed using a × 200
objective. Ten fields of each slide were counted for all
samples and repeated three times for statistical analysis.
Results were expressed as the proportion (percentage) of
labeled cells per square millimeter of synovium. For sta-
tistical analysis, the mean value obtained from the
repeated counts was used. All of the scoring and quanti-
tative analyses were assessed by two independent obser-
vers who were blinded to the origin of the sections to
avoid bias from interobserver variability.
Statistical analysis
The differences of value in each assessment between
pre- and post-arthritic evaluations were analyzed by Stu-
dent t test. The differences among the HA, SA, and No-
tr groups on each dosage (1D, 3D, and 3D6d) were ana-
lyzed using analysis of variance and later were analyzed
further by a Bonferroni post hoc method. Similar statisti-
cal analysis methods were used to test the differences
among dosages in each group. Non-parametric data
(histological synovial scoring) were analyzed using the
Kruskal-Wallis test for multiple groups and Mann-Whit-
ney U tests for between-group comparisons. The
Pearson correlation test was applied to study the corre-
lations between pain withdrawal threshold and expres-
sions of immunoreactivities. A P value of less than 0.05
was considered statistically significant. All data were
analyzed using SPSS version 10.0 for Windows (SPSS
Inc., Chicago, IL, USA).
Results
Effect of hyaluronan on complete Freund’s adjuvant-
induced edema
The serial alterations of the percentage of edema (mean
± standard error of the mean, or SEM) throughout the
whole experiment for each group are shown in Figure
2A. After a day of CFA induction, all animals developed
severe monoarthritis in the injected paw. There were no
significant differences in the non-injected intact paw on
circumference among pre- and post-arthritic and post-
treatment conditions for each group (P> 0.05, data not
shown). The edema of the CFA-injected paw gradually
increased, reaching a maximal swelling of 65.51%,
whereas there were significant differences in edema
between pre- and post-arthritic conditions (P< 0.001).
After treatment, the significant time-dependent differ-
ences in edema development were observed in each
group (HA group: P< 0.001; SA group: P< 0.001; and
No-tr group: P< 0.001). However, there was no differ-
ence in the edema of arthritic paws among the HA, SA,
and No-tr groups after treatments of 1D (P = 0.22), 3D
(P = 0.41), and 3D6d (P = 0.31). Therefore, intra-articu-
lar injections of HA, regardless of different dosages for
1D, 3D, and 3D6d, did not ameliorate joint swelling
compared with either the SA or the No-tr group.
Effect of hyaluronan on complete Freund’s adjuvant-
induced inflammatory mechanical nociception
The serial alterations of the paw withdrawal threshold
(mean ± SEM) throughout the whole experiment for
each group are shown in Figure 2B. The mean threshold
was 25.07 ± 4.68 g at pre-arthritic conditions. However,
after CFA induction, it decreased to 9.32 ± 3.16 g.
There was a significant difference with pre-arthritic con-
ditions (P< 0.001).
The significant differences in paw withdrawal thresh-
old were shown among the HA, SA, and No-tr groups
after treatment of 1D (P = 0.008), 3D (P< 0.001), and
3D6d (P< 0.001). A significantly lower threshold existed
after treatment of 1D, 3D, and 3D6d in the SA and No-
tr groups compared with those in the HA group (HA
versus SA, P = 0.04; HA versus No-tr, P =0 . 0 1f o r1 D ;
HA versus SA, P < 0.001; HA versus No-tr, P< 0.001 for
3D; HA versus SA, P< 0.001; HA versus No-tr, P =
0.001 for 3D6d). The analysis also showed that there
was a significantly lower threshold in the No-tr group
compared with the SA group after treatment of 3D (P=
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Page 4 of 13Figure 2 Results of edema (a) and pain behavioral (b) assessments. Data were calculated before treatment at the conditions of pre-
complete Freund’s adjuvant (CFA)-induced and post-CFA-induced arthritis and after treatment at conditions of one dose (1D), three doses (3D),
and follow-up at the 6th day after three doses (3D6d) in hyaluronan (HA), saline (SA), and ‘no treatment’ (No-tr) groups. Each bar represents the
mean ± standard deviation in body weight and mean ± standard error of the mean in paw circumference and withdrawal threshold.
#P< 0.05,
Student t test for comparison of pre- and post-arthritic conditions before treatment. *P< 0.05, Bonferroni post hoc test for comparison of
difference between groups at dosages of 1D, 3D, and 3D6d after treatment.
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ference was observed between these groups after treat-
ment of 1D (P=1.0).
There were significant differences among three
dosages in the HA group (P< 0.001) but not in the SA
(P = 0.84) and No-tr (P = 0.56) groups. After HA treat-
ment, the paw withdrawal threshold showed a signifi-
cant increase in 3D and 3D6d treatments compared
with 1D treatment (1D versus 3D, P< 0.001; 1D versus
3D6d, P< 0.001). However, no difference was observed
between the 3D and 3D6d of HA treatments (P = 0.05).
Histopathological assessments
Widening of the synovial cavity, infiltration of inflamma-
tory cells, thickening of the synovial membrane, narrow-
ing of the synovial space, disruption of the cartilaginous
tissue, and bone erosion were apparent in control rats
of the No-tr group (Figure 3A, 3a) and SA group (Figure
3 B ,3 b ) .T h et i b i o t a r s a lj o i n t so fr a t st r e a t e dw i t h1 D ,
3D, and 3D6d of HA were less inflamed, as revealed by
a decreased number of inflammatory cells, synovial
membrane thickening, and cartilage destruction (Figure
3C, 3c). There were significant differences in lymphocy-
tic infiltration and aggregate score of non-parametric
criteria observed among ankle joint synovium from the
HA, SA, and No-tr groups treated with 1D, 3D, and
3D6d (P < 0.05) (Table 1). Lymphocytic infiltrations in
synovium were significantly reduced after HA treatment
when compared with those treated with SA or No-tr
(HA versus SA, HA versus No-tr, P < 0.05 in all doses).
There were no significant differences in intimal hyper-
plasia, subintimal fibrosis, and vascularity among the
three groups (P > 0.05).
Immunohistochemical assessments on location of HIF-1a,
iNOS, and MMP3
Overexpressions of HIF-1a, iNOS, and MMP3 immu-
noreactivities were found within the synovial tissue in
the No-tr group (Figures 4A, 5A, and 6A) and the SA
group (Figures 4B, 5B, and 6B). At higher-power magni-
fication, it is evident that these positive immunoreactiv-
ities were clearly localized in both the nucleus and
cytoplasm of arthritic synovium (Figures 4a, 5a, 6a, 4b,
5b, and 6b). The primary cells exhibiting specific HIF-
1a, iNOS, and MMP3 immunoreactivities were morpho-
logically consistent with macrophages, mainly in inflam-
matory infiltrate and invasive pannus of the inflamed
synovial joint. Synovial lining cells and some chondro-
cytes were also found to be positive for HIF-1a,i N O S ,
and MMP3. After treatment with HA, the HIF-1a,
tarsus
tibia
syn syn
tibia
ȝP
ȝP
ABC
syn
tibia
a b c
Figure 3 Histopathology of arthritis joints. Representative hematoxylin and eosin sections of hind paws obtained from adjuvant-induced
arthritic animals treated with intra-articular injections of ‘no treatment’ (No-tr) (A), saline (SA) (B), and hyaluronan (HA) (C). In rats in the No-tr
group, in which cartilaginous tissue could not be clearly detected, bone damage was even greater and massive inflammatory cells infiltrated the
synovium (a). Similar changes were observed in rats treated with SA. Cartilage erosion was more pronounced and the extensively expanded
synovial pannus was more densely infiltrated with mononuclear cells (b). In rats treated with HA, the joints were much less inflamed, and
lymphocyte accumulation (c) and cartilage damage decreased. There was no sign of bone destruction. 1D, one dose; 3D, three doses; 3D6d,
follow-up at the 6th day after three doses; cart, cartilage; syn, synovial tissue.
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(Figures 4C, 5C, and 6C) concurrently with reduced
immunoreactivities localized in both the nucleus and
cytoplasm of arthritic synovium at higher-power magni-
fication (Figures 4c, 5c, and 6c).
Quantitative analysis of extent of HIF-1a, iNOS, and
MMP3 immunoreactive expressions
After treatment, the significant differences in extent of
HIF-1a, iNOS, and MMP3 immunoreactive expressions
were shown among the HA, SA, and No-tr groups after
treatment of 1D (HIF-1a: P< 0.001; iNOS: P< 0.001;
MMP3: P< 0.001), 3D (HIF-1a: P< 0.001; iNOS: P
<0.001; MMP3: P< 0.001), and 3D6d (HIF-1a: P< 0.001;
iNOS: P< 0.001; MMP3: P< 0.001). Significantly lower
expressions of HIF-1a, iNOS, and MMP3 immunoreac-
tivities existed after treatment of 1D in the HA group-
HIF-1a:H Av e r s u sS A ,P< 0.001; HA versus No-tr, P
<0.001 (Figure 4D); iNOS: HA versus SA, P< 0.001; HA
versus No-tr, P< 0.001 (Figure 5D); MMP3: HA versus
SA, P< 0.001; HA versus No-tr, P< 0.001 (Figure 6D).
The analysis also showed that there were no significant
differences in HIF-1a, iNOS, and MMP3 immunoreac-
tivities between the SA and No-tr groups for 1D dosage
(HIF-1a:S Av e r s u sN o - t r ,P =0 . 1 4 ;i N O S :P =0 . 4 5 ;
MMP3: P = 1.0) (Figures 4D, 5D, and 6D). Similar
results were found for HIF-1a, iNOS, and MMP3
immunoreactivities for treatments of 3D and 3D6d (Fig-
ures 4D, 5D, and 6D).
Significant differences in extent of HIF-1a, iNOS, and
MMP3 immunoreactive expressions were shown among
1D, 3D, and 3D6d dosages in the HA group (HIF-1a: P
<0.001; iNOS: P = 0.004; MMP3: P< 0.001) but not in
the SA group (HIF-1a: P =0 . 5 6 ;i N O S :P =0 . 8 5 ;
MMP3: P = 0.81) or the No-tr group (HIF-1a: P = 0.16;
iNOS: P = 0.50; MMP3: P = 0.99). After 3D and 3D6d
of HA treatment, the extent of HIF-1a and iNOS
immunoreactive expressions significantly reached maxi-
mum reduction compared with those of 1D treatment-
HIF-1a:3 Dv e r s u s1 D ,P< 0.001; 3D6d versus 1D, P=
0.03 (Figure 4D); iNOS: 3D versus 1D, P = 0.01; 3D6d
versus 1D, P = 0.03 (Figure 5D). However, no difference
was exhibited between the 3D and 3D6d of HA treat-
ments (HIF-1a:3 Dv e r s u s3 D 6 d ,P = 0.15; iNOS: 3D
versus 3D6d, P = 1.0). For expression of MMP3 immu-
noreactivity, significant reduction was found after 3D
treatment (3D versus 1D, P = 0.001; 3D versus 3D6d, P
<0.001) (Figure 6D). However, the expression of MMP3
immunoreactivity recovered after 3D6d treatment (3D6d
versus 1D, P = 1.0).
Association of pain withdrawal threshold with
immunoreactivity results
A significant linear correlation was found between pain
withdrawal threshold and immunoreactivity of HIF-1a,
iNOS, and MMP3 (Pearson correlation coefficients, P <
0 . 0 5 )( T a b l e2 ) .T h e r ew e r es t r o n gn e g a t i v ea s s o c i a t i o n s
of pain withdrawal threshold with HIF-1a,i N O S ,a n d
MMP3 after 3D treatment and with HIF-1a and MMP3
after 3D6d treatment (0.75 < | Pearson g | < 1).
Discussion
The results of this study demonstrate that lymphocytic/
plasmocytic infiltration in the synovium and accumula-
tion of HIF-1a, iNOS, and MMP3 were suppressed after
intra-articular administration of HA at the early phase
of adjuvant-induced inflammation. The extent of HIF-
1a, iNOS, and MMP3 immunoreactivities was
Table 1 Results of histopathological scores of synovium for sections in arthritic ankle joint sampled from three
treatment groups
Dose Group Intimal
hyperplasia
Subintimal
fibrosis
Lymphocytic infiltration Vascularity Aggregate
score
1D HA 2.45 ± 0.11 2.60 ± 0.11 1.50 ± 0.11
a, b 2.05 ± 0.11 7.80 ± 0.26
a, b
SA 2.60 ± 0.11 2.60 ± 0.11 2.50 ± 0.11 2.10 ± 0.12 9.10 ± 0.31
No-tr 2.65 ± 0.11 2.65 ± 0.10 2.95 ± 0.05 2.20 ± 0.12 9.75 ± 0.24
cP value among groups P > 0.05 P > 0.05 P< 0.001 P > 0.05 P< 0.001
3D HA 2.50 ± 0.11 2.70 ± 0.11 1.40 ± 0.13
a, b 2.20 ± 0.09 8.05 ± 0.31
a, b
SA 2.80 ± 0.09 2.70 ± 0.10 2.55 ± 0.11 2.15 ± 0.11 9.55 ± 0.28
No-tr 2.80 ± 0.09 2.70 ± 0.11 2.85 ± 0.08 2.20 ± 0.14 9.95 ± 0.32
cP value among groups P > 0.05 P > 0.05 P< 0.001 P > 0.05 P< 0.001
3D6d HA 2.50 ± 0.11 2.50 ± 0.11 1.40 ± 0.11
a, b 2.15 ± 0.11 7.85 ± 0.25
a, b
SA 2.70 ± 0.11 2.60 ± 0.10 2.77 ± 0.10 2.20 ± 0.14 9.6 ± 0.36
No-tr 2.70 ± 0.11 2.70 ± 0.11 2.85 ± 0.08 2.40 ± 0.11 10.05 ± 0.33
Sections were stained with hematoxylin and eosin. Values are presented as mean ± standard error of the mean.
aP < 0.05, showed statistically significant
differences between hyaluronan (HA) and saline (SA) groups;
bP < 0.05, showed statistically significant differences between HA and ‘no treatment’ (No-tr) groups;
Mann-Whitney U ranked tests were used for between-group comparisons.
cTested with Kruskal-Wallis test. 1D, one dose; 3D, three doses; 3D6d, follow-up at the
6th day after three doses.
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Figure 4 Representative immunohistochemical sections of hypoxia-inducible factor-1-alpha (HIF-1a) immunoreactivity.S e c t i o n s
obtained from the arthritic synovium treated with intra-articular injections of ‘no treatment’ (No-tr) (A), saline (SA) (B), and hyaluronan (HA) (C).
At higher-power magnification, it is evident that these positive (brown staining) immunoreactivities were clearly localized in both the nucleus
and cytoplasm of arthritic synovium in the sections from No-tr (a) and SA (b) animals. Administration of HA (c) to adjuvant-induced rat
produced a marked reduction in the immunostaining for HIF-1a. Quantitative analysis (D) of positive-labeled cells in synovium for HIF-1a
immunohistochemistry at the early phase of inflammation of each group was presented in the average proportion of labeled neurons (mean ±
standard error of the mean). *P< 0.05, showed significant differences between groups when either SA or No-tr is compared with HA group using
Bonferroni post hoc test. Significant differences were found between HA versus SA groups and HA versus No-tr groups.
#P< 0.05, showed
significant differences between dosages tested by Bonferroni post hoc test. 1D, one dose; 3D, three doses; 3D6d, follow-up at the 6th day after
three doses; cart, cartilage; syn, synovial tissue.
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Figure 5 Representative immunohistochemical sections of inducible nitric oxide synthase (iNOS) immunoreactivity. Sections obtained
from the arthritic synovium treated with intra-articular injections of ‘no treatment’ (No-tr) (A), saline (SA) (B), and hyaluronan (HA) (C). At higher-
power magnification, it is evident that these positive (brown staining) immunoreactivities were clearly localized in both the nucleus and
cytoplasm of arthritic synovium in the sections from No-tr (a) and SA (b) animals. Administration of HA (c) to adjuvant-induced rat produced a
marked reduction in the immunostaining for iNOS. Quantitative analysis (D) of positive-labeled cells in synovium for iNOS immunohistochemistry
at the early phase of inflammation of each group was presented in the average proportion of labeled neurons (mean ± standard error of the
mean). *P< 0.05, showed significant differences between groups when either SA or No-tr is compared with HA group using Bonferroni post hoc
test. Significant differences were found between HA versus SA groups and HA versus No-tr groups.
#P< 0.05, showed significant differences
between dosages tested by Bonferroni post hoc test. 1D, one dose; 3D, three doses; 3D6d, follow-up at the 6th day after three doses; cart,
cartilage; syn, synovial tissue.
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Figure 6 Representative immunohistochemical sections of matrix metalloproteinase-3 (MMP3) immunoreactivity. Sections obtained
from the arthritic synovium treated with intra-articular injections of ‘no treatment’ (No-tr) (A), saline (SA) (B), and hyaluronan (HA) (C). At higher-
power magnification, it is evident that these positive (brown staining) immunoreactivities were clearly localized in both the nucleus and
cytoplasm of arthritic synovium in the sections from No-tr (a) and SA (b) animals. Administration of HA (c) to adjuvant-induced rat produced a
marked reduction in the immunostaining for inducible nitric oxide synthase. Quantitative analysis (D) of positive-labeled cells in synovium for
MMP3 immunohistochemistry at the early phase of inflammation of each group was presented in the average proportion of labeled neurons
(mean ± standard error of the mean). *P< 0.05, showed significant differences between groups when either SA or No-tr is compared with HA
group using Bonferroni post hoc test. Significant differences were found between HA versus SA groups and HA versus No-tr groups.
#P< 0.05,
showed significant differences between dosages tested by Bonferroni post hoc test. 1D, one dose; 3D, three doses; 3D6d, follow-up at the 6th
day after three doses; cart, cartilage; syn, synovial tissue.
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Page 10 of 13consistent with the results of pain behavioral assess-
ment, which demonstrated an elevation of the mechano-
nociceptive threshold after administration of HA. To the
best of our knowledge, these findings have never been
reported by other researchers.
In this model, the early phases of adjuvant-induced
arthritis seem to be characterized by acute cytokine-
induced inflammation [25]. Owing to infiltration of the
injured tissues by immune cells and responses, swelling
is a major sign during acute inflammation and might
also be considered an important parameter on evalua-
tion of the potential anti-inflammatory effects of com-
pounds [26]. However, as shown in the results of our
study, the levels of edematous swelling were not chan-
ged after HA treatment in acute inflammation at the
early phase of adjuvant-induced arthritis, suggesting the
weaker activity against edema of HA in an acute inflam-
matory animal model. This result is consistent with the
animal study with collagen-induced arthritis [27] and
human study with OA [28]. The reason is probably due
to a HA-induced swelling adverse effect at the injection
site occurring. Previous studies revealed that HA may
act as either a primary irritant or an inflammatory med-
iator to induce acute adverse events characterized by
transient swelling of the injected joint in some patients
[28-30]. The prevalence of adverse effects was noted in
47% of patients after HA supplementation and in 22%
of patients treated with saline injections [31]. In this
study, the observation time of edema measurement
started 3 hours after HA administration, when an
adverse effect of a transient increase in swelling at the
injection site occurred. Therefore, further study with
long-term observations of joint swelling after ceasing
HA was needed to clarify the effect of exogenous HA
on resolving RA-induced joint edema.
It has been well established by animal behavioral and
human clinical studies that elastoviscous solutions of
HA could have an analgesic effect when injected into
arthritic joints and if appropriately applied to patients
with acute arthritic pain [32]. There was significantly
less bradykinin found in the crystal-induced arthritic
joint after injection of HA [33]. Electrophysiological stu-
dies also demonstrated that the rates of neural dis-
charges of the nociceptive afferent fibers innervating the
synovial tissue were significantly attenuated and reached
a constant rate 2 to 3 hours after injection [32,34,35].
Treatment of HA showed an analgesic effect after the
onset of cartilage destruction and pain in a rabbit OA
m o d e l[ 3 6 ] .T ot h eb e s to fo u rk n o w l e d g e ,o u rb e h a -
vioral study is the first report on the analgesic effect of
HA at decreased mechanical allodynia in a rat RA
model and is consistent with the findings of previous
studies. The intra-articular injection of HA also resulted
in elevation of the mechanonociceptive threshold, which
w a si na c c o r d a n c ew i t ht h er e s u l t so fi m m u n o h i s t o -
chemistry in this study. HA has been demonstrated to
possess a therapeutic effect on OA and this effect has
been studied by many researchers. Macroscopic and
microscopic evaluations revealed that HA has chondro-
protective effects in a rabbit model of OA [37]. Our
results showed that HA reduced pathohistological signs,
including the degree of infiltration of the synovial mem-
brane by plasma and lymphocytes, in collagen-induced
arthritis animals, and are consistent with findings from
a previous study [38]. The tendency for decreased cellu-
lar infiltration during the early phase of arthritis sup-
ports the assumption that HA provides a temporary
protective barrier over the cartilage and thereby protects
it against CFA insults. HA has also been shown to sig-
nificantly suppress NO production and inhibit IL-1b-
induced MMP3 production from OA synovial tissue in
vitro and in vivo [39-42]. As far as we know, few English
language studies of the role of HA on suppression of
HIF-1a-mediated hypoxic and inflammatory responses
have been conducted in OA models. Owing to less
inflammation in OA synovial tissue, there is minor HIF-
1a expression in these tissues [5]. However, there is
higher expression of HIF-1a immunohistochemistry in
RA synovial tissues compared with OA tissues because
the latter tissue, by nature, is inflammatory and angio-
genic in RA [7]. Therefore, HIF-1a has the potential to
serve as an anti-rheumatic drug activity biomarker in
the clinic and is expected to significantly affect/acceler-
ate the clinical development of treatment for RA.
The possible important role of HIF-1a in RA has been
extensively discussed [43,44]. The presence of both
hypoxia and inflammatory proteins in RA synovium,
which both lead to HIF-1a stabilization and subsequent
HIF-1 activation, seems to highlight the important role
of HIF-1a [44]. Elevated synovial angiogenesis is a key
event during the course of RA. The modulation and
blockade of angiogenesis via drug interventions have
been shown to contribute to therapeutic efficacy in rat
models of arthritis [45]. HIF-1a probably has a crucial
involvement in the angiogenic process of synovium in
Table 2 Association of pain withdrawal threshold with
the immunoreactivity results given as gamma values
Pain withdrawal threshold
1D 3D 3D6d
HIF-1a -0.378
a -0.848
a -0.869
a
iNOS -0.280
b -0.782
a -0.765
a
MMP3 -0.420
a -0.823
a -0.856
a
Correlations were analyzed by Pearson correlation coefficients.
aP < 0.01;
bP <
0.05.
1D, one dose; 3D, three doses; 3D6d, follow-up at the 6th day after three
doses; HIF-1a, hypoxia-inducible factor-1-alpha; iNOS, inducible nitric oxide
synthase; MMP3, matrix metalloproteinase-3.
Chou et al. Arthritis Research & Therapy 2011, 13:R90
http://arthritis-research.com/content/13/3/R90
Page 11 of 13RA by regulation of its target gene, vascular endothelial
growth factor (VEGF) [43]. Inhibition of HIF-1a protein
expression and VEGF production by SMP-114, a dis-
ease-modifying anti-rheumatic drug, has been shown to
be of therapeutic benefit in RA [46]. Oral administration
of the inhibitor of heat shock protein 90 (Hsp90), which
has been shown to potently reduce HIF-1a-related sig-
naling and VEGF production, has also been found to
decrease inflammation and cartilage damage in in vivo
models of RA [47]. Therefore, suppression of HIF-1a
may have key implications in the development of novel
therapeutic strategies revolutionizing the treatment of
RA. Results showed that HA suppressed the adjuvant-
induced overexpression of iNOS and MMP3, and this is
consistent with findings from previous studies. To the
best of our knowledge, our study is the first to report
that HA suppresses HIF-1a. This study revealed the
reduction of accumulation of HIF-1a expression in the
synovium of an adjuvant-induced RA model after intra-
articular HA administration. The suppressive effects on
accumulation of inflammation-induced HIF-1a,i N O S ,
and MMP3 expressions int h es y n o v i u mm a yb e
involved in the therapeutic mechanism of HA interven-
tion used in the treatment of RA. Further molecular stu-
dies on expressions of VEGF will be needed to fully
support the issue of anti-angiogenic effects of HA.
Conclusions
Suppression of HIF-1a may be one of the major tar-
gets of the therapeutic approach in RA. This study
demonstrated that early intervention of HA is an effec-
tive protection against accumulation of inflammation-
induced HIF-1a,i N O S ,a n dM M P 3a n dm i g h tl i m i t
the erosive joint damage of arthritis. The findings sug-
gest that modulation of HIF-1a as a ‘master switch’
may be used as a therapeutic target in the anti-inflam-
matory treatment of RA.
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